Status:
RECRUITING
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Lead Sponsor:
Stefan Carlsson
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate Specific Antigen (PSA) lev...
Eligibility Criteria
Inclusion
- Patients previously treated for prostate cancer with radical prostatectomy and now having a biochemical recurrence (BCR) defined as: PSA \>0.2 \<2.0 ng/mL, and increasing measured twice.
- Multidisciplinary conference (MDK) decision to offer the patient SRT
- Signed Informed Consent
Exclusion
- Patients previously treated for prostate cancer with biochemical recurrence
- Previous treatment with androgen deprivation therapy (ADT) after surgery
- Previous pelvic radiotherapy
- Patients with positive lymph nodes at surgery
Key Trial Info
Start Date :
October 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2027
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT04794777
Start Date
October 30 2018
End Date
October 30 2027
Last Update
March 20 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska University Hospital
Gothenburg, Göteborg, Sweden, 413 45
2
Södersjukhuset
Stockholm, Stockholm County, Sweden, 118 83
3
Karolinska University Hospital
Stockholm, Stockholm County, Sweden, 171 76
4
Norrland's University Hospital
Umeå, Sweden, 901 85